Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

NCT03137407 is registered in ClinicalTrials.gov with Revance Therapeutics, Inc. as lead sponsor.

NCT NCT03137407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03137407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Lead sponsor
Revance Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 12, 2017
Completion date
February 20, 2018
Enrollment
59 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

plantar fasciitis